Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy

被引：84
作者：
Barrett, Richard [1 ]
Pure, Ellen [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
来源：
CURRENT OPINION IN IMMUNOLOGY | 2020年 / 64卷
关键词：
NATURAL-KILLER-CELLS; ACTIVATION PROTEIN; PANCREATIC-CANCER; SUPPRESSOR-CELLS; ANTITUMOR IMMUNITY; STROMAL CELLS; TGF-BETA; T-CELLS; RECEPTOR; GROWTH;
D O I：
10.1016/j.coi.2020.03.004
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Immune-targeted approaches are rapidly changing the therapeutic landscape for cancer. In spite of that, most patients show resistance or acquire resistance to these therapies. Increasing work describing the tumor microenvironment (TME) has highlighted this space as one of the key determinants in tumor immune response and immunotherapeutic success. Frequently overlooked within this space, cancer-associated fibroblasts (CAFs) within the TME have surfaced as an important dictator of the tumor immune response. Herein, we review recent advances in defining the role of CAF-immune cell interactions in solid tumors and prospects for targeting stroma to overcome resistance to immunotherapy.
引用
收藏
页码：80 / 87
页数：8
相关论文
共 93 条
[1]   Podoplanin: emerging functions in development the immune system and cancer [J].
Astarita, Jillian L. ;
Acton, Sophie E. ;
Turley, Shannon J. .
FRONTIERS IN IMMUNOLOGY, 2012, 3
[2]   Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts [J].
Avery, Diana ;
Govindaraju, Priya ;
Jacob, Michele ;
Todd, Leslie ;
Monslow, James ;
Pure, Ellen .
MATRIX BIOLOGY, 2018, 67 :90-106
[3]   Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors [J].
Bahleda, Rastislav ;
Italiano, Antoine ;
Hierro, Cinta ;
Mita, Alain ;
Cervantes, Andres ;
Chan, Nancy ;
Awad, Mark ;
Calvo, Emiliano ;
Moreno, Victor ;
Govindan, Ramaswamy ;
Spira, Alexander ;
Gonzalez, Martha ;
Zhong, Bob ;
Santiago-Walker, Ademi ;
Poggesi, Italo ;
Parekh, Trilok ;
Xie, Hong ;
Infante, Jeffrey ;
Tabernero, Josep .
CLINICAL CANCER RESEARCH, 2019, 25 (16) :4888-4897
[4]  
Bahrami B, 2017, CELL J, V19, P137
[5]   Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity [J].
Balsamo, Mirna ;
Scordamaglia, Francesca ;
Pietra, Gabriella ;
Manzini, Claudia ;
Cantoni, Claudia ;
Boitano, Monica ;
Queirolo, Paola ;
Vermi, William ;
Facchetti, Fabio ;
Moretta, Alessandro ;
Moretta, Lorenzo ;
Mingari, Maria Cristina ;
Vitale, Massimo .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (49) :20847-20852
[6]   Reciprocal Functional Modulation of the Activation of T Lymphocytes and Fibroblasts Derived from Human Solid Tumors [J].
Barnas, Jennifer L. ;
Simpson-Abelson, Michelle R. ;
Brooks, Stephen P. ;
Kelleher, Raymond J., Jr. ;
Bankert, Richard B. .
JOURNAL OF IMMUNOLOGY, 2010, 185 (05) :2681-2692
[7]   Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists [J].
Beatty, Gregory L. ;
Li, Yan ;
Long, Kristen B. .
EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (02) :175-186
[8]   CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver [J].
Benedicto, Aitor ;
Romayor, Irene ;
Arteta, Beatriz .
ONCOLOGY REPORTS, 2018, 39 (04) :2022-2030
[9]   A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma [J].
Benson, Al B., III ;
Wainberg, Zev A. ;
Hecht, J. Randolph ;
Vyushkov, Dmitry ;
Dong, Hua ;
Bendell, Johanna ;
Kudrik, Fred .
ONCOLOGIST, 2017, 22 (03) :241-+
[10]   Evidence-based complementary treatment of pancreatic cancer: a review of adjunct therapies including paricalcitol, hydroxychloroquine, intravenous vitamin C, statins, metformin, curcumin, and aspirin [J].
Bigelsen, Stephen .
CANCER MANAGEMENT AND RESEARCH, 2018, 10 :2003-2018
12345678910